Sanofi-Aventis has in-licensed a technology patent from Shanghai Institutes for Biological Sciences (SIBS) that may lead to an anti-angiogenesis cancer drug. The patent covers SIBS’s discovery of the importance of the Slit-Robo signaling path for tumor vasculature and tumor growth. The total deal is woth $60 million, according to Data Monitor, which includes an upfront payment, milestones and royalties on sales. More details....

Stock Symbol: (NYSE: SNY)